Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B L Roth

Schizophrenia Risk Gene CAV1 Is Both Pro-Psychotic and Required for Atypical Antipsychotic Drug Actions in Vivo

Translational Psychiatry

Molecular Neuroscience

Biological Psychiatry

English

Related publications

Chlorpromazine Versus Atypical Antipsychotic Drugs for Schizophrenia

English

Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia

Molecular Psychiatry

Molecular Neuroscience

Molecular Biology

English

Schizophrenia Polygenic Risk Score and Psychotic Risk Detection

The Lancet Psychiatry

Biological Psychiatry

English

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

English

Pharmacoeconomic Comparison of Ziprasidone With Other Atypical Oral Antipsychotic Agents in Schizophrenia

Farmeconomia. Health economics and therapeutic pathways

English

What Is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People With Schizophrenia?

World Psychiatry

Psychiatric Mental Health

English

Microglial Intracellular Ca2+ Signaling as a Target of Antipsychotic Actions for the Treatment of Schizophrenia

Frontiers in Cellular Neuroscience

Molecular Neuroscience

English

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Frontiers in Psychiatry

English